{"organizations": [], "uuid": "5ad12d486e02c516cf2619010505a470b28c5177", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vanda-pharmaceuticals-wins-appeal/brief-vanda-pharmaceuticals-wins-appeal-case-on-fanapt-idUSFWN1RQ0LE", "country": "US", "domain_rank": 408, "title": "BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-13T19:02:00.000+03:00", "replies_count": 0, "uuid": "5ad12d486e02c516cf2619010505a470b28c5177"}, "author": "", "url": "https://www.reuters.com/article/brief-vanda-pharmaceuticals-wins-appeal/brief-vanda-pharmaceuticals-wins-appeal-case-on-fanapt-idUSFWN1RQ0LE", "ord_in_thread": 0, "title": "BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt", "locations": [], "entities": {"persons": [{"name": "vanda", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-vanda pharmaceuticals", "sentiment": "negative"}, {"name": "vanda pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 13, 2018 / 4:06 PM / Updated 38 minutes ago BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt Reuters Staff \nApril 13 (Reuters) - Vanda Pharmaceuticals Inc : * VANDA WINS APPEAL CASE ON FANAPT® \n* U.S. FEDERAL COURT AFFIRMED U.S. COURT’S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO’S U.S. ‘610 PATENT FOR FANAPT \n* ‘610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-13T19:02:00.000+03:00", "crawled": "2018-04-13T19:21:25.032+03:00", "highlightTitle": ""}